CRISPR Stocks Jump Amid Nobel Honors and Patent Filing Drama
Happy Wednesday! Since October started, markets have been in a whirlwind. But we can largely attribute that to the bold character of President Trump who has — in only the last 7 days — contracted COVID-19, scared the shit out of Wall Street, made a full recovery, and then called off stimulus talks which were largely supporting stock valuations.
However, despite all the turbulence on markets, there are still winners. We’re breaking down the big ones:
🧬 This morning, Jennifer Doudna and Emmanuelle Charpentier were awarded the Nobel Prize in Chemistry for their development of a method for genome editing. CRISPR/Cas9 has been heralded as a potential way to fix genetic disorders, create personalized medicine and even attack cancer and viruses. The importance of Doudna and Charpentier’s discovery cannot be underscored. It opens up a world of possibilities.
🧬 A few years ago, after the discovery of the CRISPR/Cas9 system, Doudna and Charpentier set out to apply this science by co-founding a number of biotech companies. Simultaneously, researcher Feng Zhang also filed a U.S. patent on the technology after proving the CRISPR/Cas9 system worked in mammalian cells. That patent has become the center of a patent battle which has plagued the CRISPR IP. This is problematic given that there is no shortage of biotechs licensing the pivotal research from different parties.
Today, on news of the award ⬇️
🧪 $NTLA, founded by Doudna, is up 20%
🧪 $CRSP Therapeutics, co-founded by Charpentier, is up 11%.
🧪 $EDIT, founded by Feng Zhang, is up nearly 11%. Editas also was founded in-part by Doudna and several other scientists.
One thing is certain: the future of CRISPR science looks bright. Many of these companies are years from pivotal trials. But rest assured, the science itself is groundbreaking. And we will be following it — as we have been — for years to come. 📈📈📈